AFAaron S. Field

Aaron S. Field

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aaron S. Field has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2003
      • Vol. 24  (8) , 1607-1611

    Relationship between Caffeine-Induced Changes in Resting Cerebral Perfusion and Blood Oxygenation Level-Dependent Signal

    by Paul J. Laurienti, Aaron S. Field, Jonathan H. Burdette, Joseph A. Maldjian, Yi-Fen Yen, Dixon M. Moody

    BACKGROUND AND PURPOSE: Recent interest has emerged in the use of pharmacologic methods to maximize blood oxygenation level-dependent (BOLD) signal intensity changes in functional MR imaging (fMRI). Adenosine antagonists, such as caffeine and theophylline, have been identified as potential agents for this purpose. The present study was designed to determine whether caffeine-induced decreases in cerebral perfusion result in enhanced BOLD responses to visual and auditory stimuli.


  • Dietary Caffeine Consumption and Withdrawal: Confounding Variables in Quantitative Cerebral Perfusion Studies?

    by Aaron S. Field, Paul J. Laurienti, Yi-Fen Yen, Jonathan H. Burdette, Dixon M. Moody

    To evaluate the effects of dietary caffeine intake and withdrawal on cerebral blood flow (CBF), as determined from a randomized, blinded, placebo-controlled study. Twenty adults (16 men, four women; age range, 24-64 years) categorized as low (mean, 41 mg/d) or high (mean, 648 mg/d) caffeine users underwent quantitative flow-sensitive alternating inversion-recovery perfusion magnetic resonance (MR) imaging twice: 90 minutes after a dose of caffeine (250 mg) on one day and after a dose of placebo on another day (randomized counterbalanced design). Doses were preceded by 30 hours of caffeine abstinence to induce withdrawal in high caffeine users. Quantitative CBF maps were gray matter (GM)-white matter (WM) segmented and subjected to region-of-interest analysis to obtain mean CBF in WM, anterior circulation GM (AGM), and posterior circulation GM (PGM). By using two-way repeated-measures analysis of variance, regional CBF data were tested for within-subject differences between caffeine and placebo and for between-subject differences related to dietary caffeine habits. Linear regression was used to determine whether dietary caffeine use predicts CBF or CBF response to caffeine. Caffeine reduced CBF (P < or =.05) by 23% (AGM, PGM) and 18% (WM) in all subjects. Postplacebo (withdrawal) CBF in high caffeine users exceeded that in low users (P < or =.05) by 31% (AGM) and 32% (WM) (PGM, not significant). Mean postcaffeine CBF reduction in AGM was 26% in high users versus 19% in low users (P < or =.05; PGM and WM, not significant). Increasing caffeine consumption predicted higher CBF (P < or =.05) in all regions: r = 0.79 (AGM), 0.57 (PGM), and 0.76 (WM). Dietary caffeine use did not predict CBF response to caffeine. Dietary caffeine consumption and withdrawal are potential confounding variables in cerebral perfusion and functional MR imaging.


    • 1 October 2002
      • Vol. 17  (2) , 751-7

    Dietary caffeine consumption modulates fMRI measures.

    by Paul J Laurienti, Aaron S Field, Jonathan H Burdette, Joseph A Maldjian, Yi-Fen Yen, Dixon M Moody

    Caffeine is the most widely used stimulant in the world. The stimulant effects of caffeine are mediated through its antagonistic properties on neuronal adenosine receptors. In addition, caffeine blocks neurovascular adenosine receptors and decreases cerebral perfusion. Although the effects of caffeine on blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging measures are extremely important, there are few studies addressing this issue in the literature. Because chronic caffeine use causes an upregulation of adenosine receptors, the differential effects of caffeine in low and high users is of particular interest. The present study was designed to test the hypothesis that caffeine has differential effects on the BOLD signal in high and low caffeine users. We demonstrated that the BOLD signal change in visual cortex was significantly greater in high users than in low users in the presence of caffeine. In addition, the magnitude of the BOLD signal was significantly correlated with caffeine consumption. We propose that the outcome observed here was due to an upregulation of adenosine receptors in high users, resulting in differential contributions of the neural and vascular effects of adenosine in the two study populations.


  • Dietary Caffeine Consumption Modulates fMRI Measures

    by Paul J. Laurienti, Aaron S. Field, Jonathan H. Burdette, Joseph A. Maldjian, Yi-Fen Yen, Dixon M. Moody


  • Open Access

    Test‐retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge

    by Yi‐Fen Yen, Aaron S. Field, Eric M. Martin, Narter Ari, Jonathan H. Burdette, Dixon M. Moody, Atsushi M. Takahashi

    The reproducibility of quantitative cerebral blood flow (CBF) measurements using MRI with arterial spin labeling and acetazolamide challenge was assessed in 12 normal subjects, each undergoing the identical experimental procedure on two separate days. CBF was measured on a 1.5T scanner using a flow-sensitive alternating inversion recovery (FAIR) pulse sequence, performed both at baseline and 12 min after intravenous administration of acetazolamide. T1 was measured in conjunction with the FAIR scan in order to calculate quantitative CBF. The CBF maps were segmented to separate gray matter (GM) from white matter (WM) for region-of-interest (ROI) analyses. Post- acetazolamide CBF values (ml/100 g/min, mean ± SD) of 87.5 ± 12.5 (GM) and 46.1 ± 10.8 (WM) represented percent increases of 37.7% ± 24.4% (GM) and 40.1% ± 24.4% (WM). Day-to-day differences in baseline CBF were −1.7 ± 6.9 (GM) and –1.4 ± 4.7 (WM) or, relative to the mean CBF over both days for each subject, −2.5% ± 11.7% (GM) and −3.8% ± 13.6% (WM) Day- to-day differences in absolute post-ACZ CBF increase were −2.5 ± 6.8 (GM) and 2.7 ± 9.4 (WM) or, relative to the mean CBF increase over both days for each subject, –4.7% ± 13.3% (GM) and 9.1% ± 26.2% (WM). Thus, FAIR- based CBF measurements show satisfactory reproducibility from day to day, but with sufficient variation to warrant caution in interpreting longitudinal data. The hemispheric asymmetry of baseline CBF and post-acetazolamide CBF increases varied within a narrower range and should be sensitive to small changes related to disease or treatment. Magn Reson Med 47:921–928, 2002.